金吾财讯 | 强生(JNJ)公布2024年第四季度业绩，营收录得225.2亿美元，按年升5.23%，预期为224.4亿美元，得益于抗癌药物的强劲销售；净利润录得34.31亿美元，按年跌15.26%，预期为47.7亿美元；每股收益为1.41美元，预期为1.79美元；经调整后每股收益为2.04美元，较上年下降近11%，但高于预期的每股2.01美元。强生公司抗癌药物的全球季度销售额增长了19%，其中多发性骨髓瘤治疗药物Darzalex的销售额超过30亿美元，比去年同期增长了20.9%。另外，公司刚刚以146亿美元收购了神经药物制造商Intra-Cellular。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.